Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated <i>TP53</i> and MDM2 up-regulation.

Oncotarget · 2017 · PMC5669876 · PMID 29137250

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Nonetheless, patients who possess TP53 mutation(s) and elevated levels of MDM2 at the same time (21 cases, 14%) exhibit a decreasing trend in the survival rate compared to others, yet devoid of statistical significance (Figure 1F ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.